Vorinostat and Azacitidine in Treating Patients With Locally Recurrent or Metastatic Nasopharyngeal Cancer or Nasal Natural Killer T-Cell Lymphoma
Conditions: Adult Nasal Type Extranodal NK/T-Cell Lymphoma; Recurrent Nasopharyngeal Keratinizing Squamous Cell Carcinoma; Recurrent Nasopharyngeal Undifferentiated Carcinoma; Stage IV Nasopharyngeal Keratinizing Squamous Cell Carcinoma; Stage IV Nasopharyngeal Undifferentiated CarcinomaInterventions: Drug: Azacitidine; Drug: Vorinostat; Other: Pharmacological Study; Other: Laboratory Biomarker AnalysisSponsor: National Cancer Institute (NCI)Active, not recruiting - verified March 2015
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Cancer | Cancer & Oncology | Carcinoma | Lymphoma | Nasopharyngeal Cancer | Research | Skin Cancer | Squamous Cell Carcinoma | Study | T-cell Lymphoma | Undifferentiated Carcinoma